These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35495284)

  • 1. STAG2 Protein Expression in Non-muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes.
    Gordon NS; Humayun-Zakaria N; Goel A; Abbotts B; Zeegers MP; Cheng KK; James ND; Arnold R; Bryan RT; Ward DG
    Eur Urol Open Sci; 2022 Apr; 38():88-95. PubMed ID: 35495284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer.
    Taber A; Park Y; Lelo A; Prip F; Xiao J; Berry DL; Chaldekas K; Jensen JB; Philips G; Kim JS; Harris BT; Dyrskjøt L; Waldman T
    Urol Oncol; 2021 Jul; 39(7):438.e1-438.e9. PubMed ID: 33712344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle-Invasive Bladder Cancer.
    Lelo A; Prip F; Harris BT; Solomon D; Berry DL; Chaldekas K; Kumar A; Simko J; Jensen JB; Bhattacharyya P; Mannion C; Kim JS; Philips G; Dyrskjøt L; Waldman T
    Clin Cancer Res; 2018 Sep; 24(17):4145-4153. PubMed ID: 29954776
    [No Abstract]   [Full Text] [Related]  

  • 4. Human epidermal growth factor receptor 2 (
    Agrawal V; Bharti N; Pandey R
    Arab J Urol; 2020 Sep; 18(4):267-272. PubMed ID: 33312739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined exome and transcriptome sequencing of non-muscle-invasive bladder cancer: associations between genomic changes, expression subtypes, and clinical outcomes.
    Goel A; Ward DG; Noyvert B; Yu M; Gordon NS; Abbotts B; Colbourne JK; Kissane S; James ND; Zeegers MP; Cheng KK; Cazier JB; Whalley CM; Beggs AD; Palles C; Arnold R; Bryan RT
    Genome Med; 2022 Jun; 14(1):59. PubMed ID: 35655252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of STAG2-Mutant Bladder Cancers by Immunohistochemistry.
    Park Y; Lelo A; Harris B; Berry DL; Chaldekas K; Kim JS; Waldman T
    Methods Mol Biol; 2023; 2684():145-151. PubMed ID: 37410232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Analysis of Differentially Mutated Genes in Non-Muscle and Muscle-Invasive Bladder Cancer in the Chinese Population by Whole Exome Sequencing.
    Wang F; Dong X; Yang F; Xing N
    Front Genet; 2022; 13():831146. PubMed ID: 35419031
    [No Abstract]   [Full Text] [Related]  

  • 8. STAG2 expression is associated with adverse survival outcomes and regulates cell phenotype in muscle-invasive bladder cancer.
    Athans S; Krishnan N; Ramakrishnan S; Cortes Gomez E; Lage-Vickers S; Rak M; Kazmierczak Z; Ohm J; Attwood K; Wang J; Woloszynska A
    Cancer Res Commun; 2022 Oct; 2(10):1129-1143. PubMed ID: 36275363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes.
    Taylor CF; Platt FM; Hurst CD; Thygesen HH; Knowles MA
    Hum Mol Genet; 2014 Apr; 23(8):1964-74. PubMed ID: 24270882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Implications of Immunohistochemical Biomarkers in Non-muscle-invasive Blad Cancer and Muscle-invasive Bladder Cancer.
    Boegemann M; Krabbe LM
    Mini Rev Med Chem; 2020; 20(12):1133-1152. PubMed ID: 27173513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder Cancer.
    Kitchen MO; Bryan RT; Haworth KE; Emes RD; Luscombe C; Gommersall L; Cheng KK; Zeegers MP; James ND; Devall AJ; Fryer AA; Farrell WE
    PLoS One; 2015; 10(9):e0137003. PubMed ID: 26332997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study.
    Grossmann NC; Rajwa P; Quhal F; König F; Mostafaei H; Laukhtina E; Mori K; Katayama S; Motlagh RS; Fankhauser CD; Mattei A; Moschini M; Chlosta P; van Rhijn BWG; Teoh JYC; Compérat E; Babjuk M; Abufaraj M; Karakiewicz PI; Shariat SF; Pradere B
    Eur Urol Open Sci; 2022 May; 39():14-21. PubMed ID: 35528782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review.
    Soukup V; Čapoun O; Cohen D; Hernández V; Babjuk M; Burger M; Compérat E; Gontero P; Lam T; MacLennan S; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Yuan Y; Zigeuner R
    Eur Urol; 2017 Nov; 72(5):801-813. PubMed ID: 28457661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adhesion GPR123 is an indicator for recurrence and prognosis in bladder cancer.
    Liu Y; Wang G; Cui T; Lv L
    Genes Genomics; 2021 Nov; 43(11):1317-1325. PubMed ID: 33945147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
    Babjuk M; Burger M; Compérat EM; Gontero P; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Zigeuner R; Capoun O; Cohen D; Escrig JLD; Hernández V; Peyronnet B; Seisen T; Soukup V
    Eur Urol; 2019 Nov; 76(5):639-657. PubMed ID: 31443960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prognostic immune predictor, HLA-DRA, plays diverse roles in non-muscle invasive and muscle invasive bladder cancer.
    Piao XM; Kang HW; Jeong P; Byun YJ; Lee HY; Kim K; Seo SP; Kim WT; Lee JY; Ha YS; Choi YH; Moon SK; Yun SJ; Kim WJ
    Urol Oncol; 2021 Apr; 39(4):237.e21-237.e29. PubMed ID: 33339725
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Pignot G; Le Goux C; Vacher S; Schnitzler A; Radvanyi F; Allory Y; Lallemand F; Delongchamps NB; Zerbib M; Terris B; Damotte D; Bieche I
    Oncol Lett; 2019 Oct; 18(4):3471-3480. PubMed ID: 31516565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
    Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
    Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.